Literature DB >> 1352165

The Nithsdale schizophrenia surveys. IX: Akathisia, parkinsonism, tardive dyskinesia and plasma neuroleptic levels.

R G McCreadie1, L J Robertson, D H Wiles.   

Abstract

Of all known schizophrenics living in Nithsdale, south-west Scotland, 146 (88%) were examined for the presence of the three principal movement disorders secondary to antipsychotic medication, namely akathisia, tardive dyskinesia and Parkinsonism. Of these, 18% had akathisia, 5% pseudoakathisia, 29% tardive dyskinesia, 8% persistent tardive dyskinesia, and 27% Parkinsonism. No movement disorder was seen in 445, 36% had one and 20% had more than one movement disorder. Plasma neuroleptic levels at the time of clinical assessment were measured by the radioreceptor technique. Correlations between dose and plasma level were low; the ratio of mean plasma concentration to mean dose was greatest with fluphenazine decanoate and lowest for sulpiride. The concentration:dose ratio was higher in the elderly. There was no relationship between neuroleptic levels and akathisia, Parkinsonism or tardive dyskinesia. Additional psychotropic medication influenced neuroleptic levels. In 9% of patients receiving oral antipsychotic medication, no drug was detected in plasma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1352165     DOI: 10.1192/bjp.160.6.793

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  9 in total

1.  Ethical and Policy Considerations in the Application of Pharmacogenomic Testing for Tardive Dyskinesia: Case Study of the Dopamine D3 Receptor.

Authors:  Michel C F Shamy; Clement Zai; Vincenzo S Basile; James L Kennedy; Daniel J Müller; Mario Masellis
Journal:  Curr Pharmacogenomics Person Med       Date:  2011-06-01

2.  The role of estrogen in schizophrenia.

Authors:  M V Seeman
Journal:  J Psychiatry Neurosci       Date:  1996-03       Impact factor: 6.186

Review 3.  Neuroleptic-induced dysphagia: case report and literature review.

Authors:  Rainer Dziewas; Tobias Warnecke; Martina Schnabel; Martin Ritter; Darius G Nabavi; Matthias Schilling; E Bernd Ringelstein; Thomas Reker
Journal:  Dysphagia       Date:  2006-10-06       Impact factor: 3.438

4.  The Nithsdale schizophrenia surveys. An overview.

Authors:  R G McCreadie
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1992-01       Impact factor: 4.328

Review 5.  Long-term depot antipsychotics. A risk-benefit assessment.

Authors:  T R Barnes; D A Curson
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

6.  Managing antipsychotic-induced acute and tardive dystonia.

Authors:  M Raja
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

7.  Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population.

Authors:  Sven Janno; Matti M Holi; Katinka Tuisku; Kristian Wahlbeck
Journal:  BMC Neurol       Date:  2005-03-17       Impact factor: 2.474

8.  A survey of the tardive dyskinesia induced by antipsychotic drugs in patients with schizophrenia.

Authors:  Sahel Hemmati; Ali Nazeri Astaneh; Farin Solemani; Roshanak Vameghi; Firouzeh Sajedi; Naser Tabibi
Journal:  Iran J Psychiatry       Date:  2010

9.  Neuroleptic-induced movement disorders in a naturalistic schizophrenia population: diagnostic value of actometric movement patterns.

Authors:  Sven Janno; Matti M Holi; Katinka Tuisku; Kristian Wahlbeck
Journal:  BMC Neurol       Date:  2008-04-18       Impact factor: 2.474

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.